1.

Introduction
Monitoring of the serum biomarkers a-fetoprotein (AFP), the b-subunit of human chorionic gonadotropin (bHCG), and lactate dehydrogenase (LDH) is a cornerstone of clinical management of testicular germ cell tumours (GCTs) [1] . However, these markers are expressed in <60% of cases, so novel sensitive markers are needed [2] . Although many substances have been suggested as biomarkers for GCT, none have qualified for clinical use [3] .
In 2011, microRNAs (miRNAs) of the clusters miR-371-3 and miR-302/367 were suggested as new serum biomarkers [4] . The miRNA molecules represent a particular class of small RNAs consisting of approximately 20 base pairs [5] . After release from the cell, these molecules remain stable in extracellular fluids [6] and can be measured by quantitative polymerase chain reaction (qPCR).
The miRNAs of the miR-371-3 and miR-302/367 clusters were originally detected in GCT tissue [7] [8] [9] [10] and four independent pilot studies confirmed elevated serum levels [11] [12] [13] [14] [15] . Furthermore, circulating miRNAs of the two clusters are clearly specific for GCT because it was demonstrated that they are absent in other malignancies [16] , and much higher levels of these miRNAs were found in testicular vein blood than in the peripheral circulation [17] . The goal of the present study was to further evaluate the usefulness of miR-371a-3p, miR-372-3p, miR-373-3p, and miR-367-3p as serum biomarkers of GCT in an unselected large patient sample. To determine whether the four miRNAs would be equally appropriate as serum biomarkers, all were tested in a preliminary study consisting of 50 GCT patients. The miRNA with the highest discriminatory power was then further evaluated in a cohort of 166 patients. We explored the utility of that miRNA as a serum biomarker by comparing its sensitivity to that of classical markers and by monitoring the response of miRNA levels to treatment.
2.
Patients and methods 
Laboratory methods
For RNA isolation, an miRNeasy Mini Kit (Qiagen, Hilden, Germany) was used to extract total RNA from 200 ml of serum. Reverse transcription (RT) was performed using a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany). The RT product was preamplified, and levels of miR-371a-3p (assay 002124), miR-372-3p (assay 000560), miR-373-3p (assay 000561), and miR-367-3p (assay 000555) were measured by qPCR using a TaqMan miRNA assay (Applied Biosystems). Cycle threshold (C t ) values were normalised to miR-93-5p (assay 000432) as an internal control, and the relative quantity (RQ) was calculated using the 2 ÀDDCt method [18] . Details of the measurement methods are described in the Supplementary methods [19] .
The classical serum tumour markers AFP, bHCG, and LDH were measured according to laboratory guidelines [20] . Preoperative values were available for 139 patients. 
Statistical analysis
Median RQ values for independent subgroups were compared using the 
Results
Preliminary study
The preliminary study revealed a significantly higher level of expression for each of the four miRNAs in GCT patients compared to controls ( Fig. 1A -D), with significance retained after correction for multiple testing (p < 0.001 for all miRNAs). Patients with metastases had higher expression levels than those with CS1 disease, but after Bonferroni correction this difference was only significant for miR-371a-3p (p = 0.001) and miR-367-3p (p = 0.006). Of the four miRNAs, miR-371a-3p had the highest ability to discriminate between patients and controls. The difference in median RQ values for controls and patients was greatest for miR-371a-3p, whereas the interquartile ranges for miR-372-3p and miR-373-3p in patients overlapped considerably with those for controls. Thus, of the four miRNAs tested, miR-371a-3p had the highest sensitivity and specificity (area under the curve [AUC] 0.943; 95% CI 0.874-0.982) according to ROC analyses with density estimation (Fig. 1E-H) .
When the four miRNAs were tested together as one marker panel with the assumption that one increased miRNA constituted an overall positive score, maximum efficiency (highest Youden index) was obtained, with sensitivity of 92% and specificity of 80%. miR-371a-3p reached specificity of 84.7% when set to the same sensitivity of 92%. Because the discriminatory power of miR-371a-3p alone was at least similar to that of the miRNA panel, only miR-371a-3p was selected for further analysis in the extended patient sample.
3.2.
Main study Figure 2A shows the median expression of miR-371a-3p in controls, in patients with LCTs, and in the three clinical GCT stages in conjunction with postoperative measurements in patients with CS1 and CS2. We observed highly significant differences in preoperative median values between GCT subgroups and controls or patients with LCTs. Significant differences were also noted between preoperative and postoperative values in CS1 and CS2 patients. Stratifying GCT patients into various histologic subgroups ( Fig. 2B ) revealed that teratoma had very low median expression, close to the normal range, in patients with CS1 and CS2 disease. Among CS1 patients, miRNA levels in seminoma and nonseminoma were significantly different from each other and from teratoma. The median miRNA levels for the subgroups featured in Figure 2A ,B are listed in Supplementary Table 8 with p values related to the various cross-comparisons shown in Supplementary  Table 9 .
The diagnostic sensitivity of miR-371a-3p was calculated to as 88.7% (95% CI 82.5-93.3%) using empirical data for all 150 preoperative samples and 106 controls, and the specificity was 93.4% (95% CI 86.9-97.3%), with an AUC of 0.945 (asymptotic 95% CI 0.916-0.974). Using the density estimation model, sensitivity was 86.3% (95% CI 79.7-90.4%) and specificity was 92.5% (95% CI 89.0-95.9%), with an AUC of 0.939 (95% CI 0.907-0.965) (Fig. 2C , Supplementary Fig. 1 ). We also found dissimilar miR expression between localized and disseminated disease, with sensitivity of 81.4% (95% CI 72.1-87.0%) and specificity of 92.5% (95% CI 89.0-96.1%) in CS1 (n = 107), and sensitivity of 98.6% (95% CI 94.8-99.9%) and specificity of 92.5% (95% CI 88.9-96.3%) in CS2-3 (n = 43).
In CS1 seminoma, multiple regression analysis revealed a highly significant association between miR-371a-3p expression and tumour diameter (p < 0.001), but no association with pT stage (Fig. 3) . Figure 4 shows the superior sensitivity of miR-371a-3p compared to the classical GCT markers in both histologic subgroups (all comparisons p < 0.001). For the entire group of 139 GCT patients for whom all values were available, the overall sensitivity of miR-371a-3p was considerably higher than that of the combined AFP, bHCG, and LDH markers (87.8% vs 50.4%). Further details are given in Supplementary  Table 10 .
The individual repeated measurements of miR-371a-3p among 18 CS2 patients during chemotherapy are shown in Figure 5A . Expression of miR-371a-3p decreased in 12 patients after orchiectomy and dropped to the normal range in the majority of patients after the first cycle of chemotherapy, remaining there during the later course. In one patient (case #118) miR-371a-3p expression was approximately 20% of the starting value until cycle 3, but then dropped to zero. On completion of therapy, most patients had miR-371a-3p expression of almost zero; two patients had expression of 1.5% and 2.2%, respectively, of the starting value.
In the nine CS3 patients, miR-371a-3p expression decreased markedly for all except one after the first cycle of chemotherapy (Fig. 5B) . No further information is available for this patient. miR-371a-3p expression levels in the other patients remained low until completion of treatment. Figure 5C shows individual miR-371a-3p expression in nine patients with relapse, all of whom had elevated expression levels. As with the other patients with metastases, miR-371a-3p levels decreased after the first cycle of chemotherapy, with one exception (case #159). Levels remained low for all patients except one (case #163), in whom miR-371a-3p expression increased to >300% of the starting value. In this case, the course of miR-371a-3p [ ( F i g . _ 2 ) T D $ F I G ] expression mirrored that of AFP levels, which likewise rose to >300%, indicating tumour progression.
[ ( F i g . _ 4 ) T D $ F I G ]
One patient with CS1 seminoma relapsed 2 yr after adjuvant carboplatin treatment (Fig. 5D ). Notably, this patient had persistently high miRNA expression after orchiectomy. The level had further increased at relapse, but dropped to normal on remission after chemotherapy.
Discussion
The study results reveal that serum levels of miR-371a-3p apparently fulfil all prerequisites for a valuable biomarker.
First, miR-371a-3p is biologically specific for GCT, although, theoretically, an immune response reaction cannot be completely excluded. Healthy control subjects and patients with nonmalignant scrotal disease, as well as those with non-GCT of the testis (LCT), did not express the marker [13, 14] . Second, the marker expression correlated with clinical stage. Patients with metastases had significantly higher miRNA levels than CS1 cases. In CS1 seminoma, miR-371a-3p levels correlated with tumour size. Third, miRNA levels correlated with treatment effects. In CS1 disease, elevated miR-371a-3p levels dropped to normal postoperatively, mirroring the tumour-free situation. In patients with metastases, miR-371a-3p expression decreased with chemotherapy to reach normal levels on completion of therapy. Notably, patients with relapsing disease also expressed the marker, as observed in nine cases. In addition, failure of therapy can be highlighted by the marker, as observed in one relapsing patient who had increasing miRNA levels on disease progression despite chemotherapy. It is also noteworthy that one patient with CS1 disease that relapsed after 2 yrs had supranormal postoperative miR-371a-3p expression. Persistent miRNA elevation might have heralded pending clinical relapse. Overall, serum miR-371a-3p levels adequately correlated with the actual state of disease and treatment response. The association between miRNA expression levels and histologic subtype is unexplained. However, it could be hypothesised that correlation between the degree of morphologic tumour differentiation and miRNA serum levels exists because the miR-371-3 cluster is expressed primarily in undifferentiated stem cells [22] . This would explain the low expression in teratoma, which represents the GCT subtype with the highest degree of morphologic differentiation [23] . Conversely, the higher expression of miR-371a-3p in nonseminoma could be related to the high proportion of embryonal carcinoma in our nonseminoma group. This histologic subtype is biologically close to stem cells [24] . By contrast, seminoma cells have a somewhat higher degree of differentiation, with morphologic similarity to spermatogonia [25] , and thus feature lower miR-371a-3p expression than embryonal carcinoma.
Since 2012, pilot studies have documented the applicability of miRNAs of the 302/367 and 371-3 clusters as serum markers of GCT. Accordingly, it was proposed that all miRNAs of the two clusters be used as one diagnostic panel in clinical practice. The present study confirms that miR-371a-3p is the miRNA with the highest ability to discriminate GCT patients from control subjects [14] . MiR-367-3p performed second best, whereas miR-372-3p and miR-373-3p had considerably lower discriminatory power.
The optimised quantification methods used in this study revealed that miR-371a-3p has specificity at least identical to the panel of four miRNAs when the sensitivity was set to an equal value. In practice, it is probably not necessary to use the panel of all miRNAs, as previously suggested [13, 15, 26, 27] . In light of the economic constraints in clinical practice and the results of the present study, it seems rational to use miR-371a-3p exclusively, adding only miR-367-3p for unresolved cases.
[ ( F i g . _ 5 ) T D $ F I G ] The diagnostic specificity of miR-371a-3p is extraordinarily high compared to the classical AFP, bHCG, and LDH markers. More than 86% of GCT patients express this novel marker. The expression is most valuable in seminoma, in which <20% of patients express bHCG [28] . Because miRNA expression is associated with tumour size, small CS1 seminomas may have only slightly increased levels. A minor limitation of the utility of miR-371a-3p is its lack of expression in teratoma. However, this finding is in accordance with the lack of expression of classical markers in this histologic subtype [29] .
Limitations of our study include the comparatively low number of patients with metastases. Owing to the somewhat dissimilar expression of the new marker in localized and systemic disease, confounding of the results by selection is conceivable, so the clinical applicability of the test remains uncertain so far. Long-term observational data are missing, and it has still not been formally proven that low miRNA levels on completion of treatment remain low. Nevertheless, preliminary data indicate that levels remain low during follow-up unless the disease recurs.
Conclusions
The promising results from pilot studies were confirmed. To the best of our knowledge, this study is the first to use density estimation for a large sample size to gauge the real distribution of RQ values for GCTs and controls. The study also provides evidence of changes in miR-371a-3p expression during chemotherapy in a fairly sizeable patient sample and documents miR expression in relapsing patients. miR371a-3p appears to be a highly sensitive and specific serum GCT biomarker that can aid during monitoring of GCT and could possibly help in sparing radiologic examinations [30] . A prospective large-scale validation study is under way with a view to implementing the test in clinical practice. Other: None. 
